CytomX Therapeutics Appoints New CMO, CSO, and Directors
Ticker: CTMX · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, executive-appointment
TL;DR
CytomX shakes up leadership with new CMO, CSO, and board members appointed Jan 30, 2025.
AI Summary
CytomX Therapeutics, Inc. announced on January 30, 2025, changes in its executive and director roles. Dr. Sean E. MacLeod has been appointed as the new Chief Medical Officer, and Dr. Michael J. Ybarra has been appointed as the new Chief Scientific Officer. Additionally, Dr. MacLeod has been appointed as a director, and Mr. David J. E. Smith has been appointed as a director. These appointments are effective as of January 30, 2025.
Why It Matters
The appointment of new key scientific and medical leadership, along with new directors, signals a potential shift in strategic direction or execution for CytomX Therapeutics' drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate strategic shifts or internal challenges, requiring investors to monitor future performance closely.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- Dr. Sean E. MacLeod (person) — Appointed Chief Medical Officer and Director
- Dr. Michael J. Ybarra (person) — Appointed Chief Scientific Officer
- Mr. David J. E. Smith (person) — Appointed Director
- January 30, 2025 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer (CMO) of CytomX Therapeutics?
Dr. Sean E. MacLeod has been appointed as the new Chief Medical Officer.
What is the effective date for the new appointments at CytomX Therapeutics?
The appointments are effective as of January 30, 2025.
Besides the CMO, who else has been appointed to a scientific leadership role?
Dr. Michael J. Ybarra has been appointed as the new Chief Scientific Officer.
Which individuals have been appointed to the Board of Directors?
Dr. Sean E. MacLeod and Mr. David J. E. Smith have been appointed as directors.
What is the principal executive office address for CytomX Therapeutics?
The principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-02-03 16:02:29
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
Filing Documents
- d924316d8k.htm (8-K) — 23KB
- 0001193125-25-019257.txt ( ) — 145KB
- ctmx-20250130.xsd (EX-101.SCH) — 3KB
- ctmx-20250130_lab.xml (EX-101.LAB) — 18KB
- ctmx-20250130_pre.xml (EX-101.PRE) — 11KB
- d924316d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 3, 2025 CYTOMX THERAPEUTICS, INC. By: /s/ Lloyd Rowland Lloyd Rowland Senior Vice President, General Counsel